| Revenue | DKK 2,5M | -38% |
| EBITDA | DKK 114K | -93% |
| Net profit | DKK -156K | -113% |
| Total assets | DKK 7,6M | +0% |
| Equity | DKK 6M | -3% |
| Employees | 7 | — |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2.701 | 2.914 | 3.257 | 4.011 | 2.476 |
| Staff expenses | -367 | -587 | -1.528 | -2.371 | -2.362 |
| EBITDA | 2.334 | 2.327 | 1.729 | 1.639 | 114 |
| Depreciation & amort. | -16 | -201 | -239 | -159 | -335 |
| EBIT | 2.318 | 2.127 | 1.490 | 1.480 | -221 |
| Net financials | -3 | -10 | -5 | -1 | 1 |
| Profit before tax | 2.315 | 2.117 | 1.485 | 1.480 | -220 |
| Tax | 400 | 371 | 265 | 283 | -63 |
| Net profit | 1.914 | 1.746 | 1.220 | 1.196 | -156 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2.787 | 4.777 | 6.464 | 7.540 | 7.561 |
| Equity | 1.985 | 3.731 | 4.951 | 6.148 | 5.991 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 432 | 396 | 621 | 261 | 294 |
| Total debt | 432 | 396 | 621 | 261 | 294 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
PS Management | Management | 2019 |
AJ Management | Management | 2019 |
ID Management | Management | 2019 |
CB Management | Management | 2019 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 25–33.32% | 25–33.32% | 2019 | |
| Company | 25–33.32% | 25–33.32% | 2019 | |
| Company | 15–19.99% | 15–19.99% | 2019 | |
| Company | 15–19.99% | 15–19.99% | 2019 | |
| Company | 10–14.99% | 10–14.99% | 2021 |
| Person | Role here | Other companies |
|---|---|---|
| Pavels Saulins | Management | 0 companies |
| Aleksandr Jakovlev | Management | 0 companies |
| Iulian Drug | Management | 0 companies |
| Cristian Bercu | Management | 0 companies |